FDA cancels drug sale licences of Cipla Pharma & Life Sciences' Pune Carry and Forwarding unit
The Maharashtra FDA has cancelled the drug sale licences of a Cipla Pharma & Life Sciences unit in Pune due to serious storage and compliance irregularities. The action follows the company's failure to properly recall misbranded medication and maintain adequate warehouse standards.
Why it matters
Regulatory enforcement in the pharmaceutical sector is essential for maintaining public health standards and ensuring drug safety.
The Maharashtra Food and Drug Administration has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) unit in Pune over serious irregularities related to the packaging, storage and recall of Reactin Plus Tablets, the regulator said.
The FDA said in a statement issued on Friday (August 28, 2026) that the cancellation came into effect on August 27, following an inspection of its main warehouse at Wadki in Pune district.
The regulator had found that medicines were stored directly on the floor and flagged deficiencies in procedures for handling expired medicines.
During an inspection around June this year, officials found that the packaging of Reactin Plus tablets, a Schedule H prescription medicine, carried an unauthorised claim describing it as an "analgesic and antipyretic", the statement said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in